⌕
Harmony Biosciences Holdings · HRMY · Nasdaq
Tenet 81 · Strong
Compare
$33.01+0.15%At closeTenet 81 · Strong
$33.01+0.05 (+0.15%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Harmony Biosciences Holdings (HRMY) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is HRMY's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Zacks Investment ResearchNov 5, 2026 · 15:06 ET
HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth

Harmony Biosciences' Q3 earnings missed estimates as higher costs weighed on profits, while Wakix demand and pipeline progress supported its 2026 revenue outlook.…

HRMY +0.2% todayRead at source ↗
● Seeking AlphaNov 4, 2026 · 18:34 ET
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2026 Earnings Call Transcript

Harmony Biosciences Holdings, Inc. (HRMY) Q3 2026 Earnings Call Transcript…

HRMY +0.2% todayRead at source ↗
● MarketBeatNov 4, 2026 · 13:17 ET
Harmony Biosciences Q3 Earnings Call Highlights

Harmony Biosciences NASDAQ: HRMY reported third-quarter net revenue of $269 million, up from $239 million a year earlier, as demand for its narcolepsy treatment WAKIX continued to grow. The company reiterated its full-ye…

HRMY +0.2% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 09:56 ET
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Lag Estimates

Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.81 per share, missing the Zacks Consensus Estimate of $1 per share. This compares to earnings of $0.87 per share a year ago.…

HRMY +0.2% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile

WAKIX ® Net Revenue in Q3 of $269 Million; Driven by Strong Demand with 400 Net Patient Adds in the Quarter; Reiterates Full Year Guidance of $1.0B to $1.04B…

HRMY +0.2% todayRead at source ↗
● Zacks Investment ResearchOct 28, 2026 · 11:01 ET
Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth

Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

HRMY +0.2% todayRead at source ↗
● Zacks Investment ResearchOct 22, 2026 · 12:41 ET
HRMY or ARGX: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and argenex SE (ARGX). But which of these two stocks offers value investors a better ban…

HRMY +0.2% todayRead at source ↗
● Zacks Investment ResearchOct 22, 2026 · 10:41 ET
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and …

HRMY +0.2% todayRead at source ↗
● BarronsOct 22, 2026 · 00:19 ET
Revisiting Former Stock Picks Marriott, Logitech, Harmony Biosciences

Technical indicators have turned bullish for the Barron's Investor Circle stock picks.…

HRMY +0.2% todayRead at source ↗
● Seeking AlphaOct 21, 2026 · 02:46 ET
Harmony Biosciences: A Cash Machine With A Patent Ruling Hanging Over It

Harmony Biosciences is rated Buy with a 12-month price target of $43, reflecting strong cash generation and WAKIX growth. HRMY's valuation is supported by WAKIX's robust performance, cash reserves, and limited downside i…

HRMY +0.2% todayRead at source ↗
● GlobeNewsWireOct 20, 2026 · 08:05 ETCOMPANY'S OWN WORDS
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026

PLYMOUTH MEETING, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report third quarter 2026 financial results on Wednesday, November 4, 2026, before t…

HRMY +0.2% todayRead at source ↗
● Defense WorldOct 19, 2026 · 08:07 ET
Harmony Biosciences (NASDAQ:HRMY) Earns “Buy” Rating from Needham & Company LLC

Harmony Biosciences (NASDAQ: HRMY - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at Needham and Company LLC in a research note issued on Monday, Benzinga reports. They presently have a $50.00 pric…

HRMY +0.2% todayRead at source ↗
● Zacks Investment ResearchOct 16, 2026 · 09:15 ET
HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth?

Harmony Biosciences gains 27.6% in six months as Wakix sales surge and pipeline advances, with new formulations and clinical milestones offering further growth opportunities.…

HRMY +0.2% todayRead at source ↗
● Fool - Investing NewsOct 12, 2026 · 19:16 ET
Why Harmony Biosciences Stock Got Mashed on Monday

Investors weren't cheered by a major change in the company's leadership.…

HRMY +0.2% todayRead at source ↗
● Defense WorldOct 12, 2026 · 11:22 ET
Harmony Biosciences (NASDAQ:HRMY) Shares Gap Down – What’s Next?

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY - Get Free Report) gapped down prior to trading on Monday. The stock had previously closed at $40.28, but opened at $38.34. Harmony Biosciences shares last traded at $38.6…

HRMY +0.2% todayRead at source ↗
● Defense WorldOct 12, 2026 · 10:46 ET
Head to Head Review: Harmony Biosciences (NASDAQ:HRMY) versus PainReform (NASDAQ:PRFX)

Harmony Biosciences (NASDAQ: HRMY - Get Free Report) and PainReform (NASDAQ: PRFX - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the s…

HRMY +0.2% todayRead at source ↗
● Investors Business DailyOct 12, 2026 · 10:14 ET
Harmony Bio CEO Plans His Exit, And Shares Take An Unharmonious Hit

Harmony Biosciences stock took a tumble Monday after its announced the transition of current CEO Jeffrey Dayno at the end of the year.…

HRMY +0.2% todayRead at source ↗
● Zacks Investment ResearchOct 6, 2026 · 12:41 ET
HRMY vs. CSLLY: Which Stock Is the Better Value Option?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive …

HRMY +0.2% todayRead at source ↗
● Zacks Investment ResearchOct 6, 2026 · 10:41 ET
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and …

HRMY +0.2% todayRead at source ↗
● GlobeNewsWireOct 1, 2026 · 08:05 ETCOMPANY'S OWN WORDS
Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days

PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, i…

HRMY +0.2% todayRead at source ↗
● Defense WorldSep 21, 2026 · 05:10 ET
Insider Selling: Harmony Biosciences (NASDAQ:HRMY) Insider Sells $34,400.00 in Stock

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY - Get Free Report) insider Kumar Budur sold 800 shares of the firm's stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $43…

HRMY +0.2% todayRead at source ↗
● Defense WorldSep 20, 2026 · 05:23 ET
Kumar Budur Sells 1,800 Shares of Harmony Biosciences (NASDAQ:HRMY) Stock

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY - Get Free Report) insider Kumar Budur sold 1,800 shares of the business's stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $…

HRMY +0.2% todayRead at source ↗
● Defense WorldSep 8, 2026 · 03:59 ET
Sonoma Pharmaceuticals (NASDAQ:SNOA) & Harmony Biosciences (NASDAQ:HRMY) Critical Analysis

Harmony Biosciences (NASDAQ: HRMY - Get Free Report) and Sonoma Pharmaceuticals (NASDAQ: SNOA - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based o…

HRMY +0.2% todayRead at source ↗
● Zacks Investment ResearchSep 3, 2026 · 12:31 ET
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?

Harmony Biosciences (HRMY) reported earnings 30 days ago. What's next for the stock?…

HRMY +0.2% todayRead at source ↗
● GlobeNewsWireSep 3, 2026 · 08:05 ETCOMPANY'S OWN WORDS
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company's investigation of EPX-100 (clemizole hydrochl…

HRMY +0.2% todayRead at source ↗
● GlobeNewsWireAug 27, 2026 · 08:05 ETCOMPANY'S OWN WORDS
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Hea…

HRMY +0.2% todayRead at source ↗

No upcoming events in the feeds.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just HRMY · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.